Novel vaccine delivery systems: solutions to HIV vaccine dilemmas?SUTTER, Gerd; HAAS, Jürgen.AIDS (Supplement). 2001, Vol 15, pp S139-S145, issn 1350-2840, SUP5Article

Protective efficacy of Modified Vaccinia virus Ankara in preclinical studiesVOLZ, Asisa; SUTTER, Gerd.Vaccine. 2013, Vol 31, Num 39, pp 4235-4240, issn 0264-410X, 6 p.Article

Poxvirus VectorsKREIJTZ, Joost H.C.M; GILBERT, Sarah C; SUTTER, Gerd et al.Vaccine. 2013, Vol 31, Num 39, issn 0264-410X, 46 p.Serial Issue

Improved host range selection for recombinant modified vaccinia virus AnkaraSTAIB, Caroline; LÖWEL, Marianne; ERFLE, Volker et al.BioTechniques. 2003, Vol 34, Num 4, pp 694-700, issn 0736-6205, 4 p.Article

Inactivation of the viral interleukin 1β receptor improves CD8⁺ T-cell memory responses elicited upon immunization with modified vaccinia virus ankaraSTAIB, Caroline; KISLING, Sigrid; ERFLE, Volker et al.Journal of general virology. 2005, Vol 86, pp 1997-2006, issn 0022-1317, 10 p., 7Article

Generation of recombinant fowlpox virus using the non-essential F11L orthologue as insertion site and a rapid transient selection strategyBOULANGER, Denise; BAIER, Robert; ERFLE, Volker et al.Journal of virological methods. 2002, Vol 106, Num 1, pp 141-151, issn 0166-0934, 11 p.Article

Reflections on the early development of poxvirus vectorsMOSS, Bernard.Vaccine. 2013, Vol 31, Num 39, pp 4220-4222, issn 0264-410X, 3 p.Article

Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteinsOLSZEWSKA, Wieslawa; SUEZER, Yasemin; SUTTER, Gerd et al.Vaccine. 2004, Vol 23, Num 2, pp 215-221, issn 0264-410X, 7 p.Article

Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat modelWEIDINGER, Gerald; OHLMANN, Marion; SCHLERETH, Bernd et al.Vaccine. 2001, Vol 19, Num 20-22, pp 2764-2768, issn 0264-410XArticle

Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus AnkaraSTAIB, Caroline; SUEZER, Yasemin; KISLING, Sigrid et al.Journal of general virology. 2006, Vol 87, pp 2917-2921, issn 0022-1317, 5 p., 10Article

HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathwayHERRMANN, Felix; LEHR, Hans-Anton; DREXLER, Ingo et al.Cancer research (Baltimore). 2004, Vol 64, Num 1, pp 215-220, issn 0008-5472, 6 p.Article

Clinical development of Modified Vaccinia virus Ankara vaccinesGILBERT, Sarah C.Vaccine. 2013, Vol 31, Num 39, pp 4241-4246, issn 0264-410X, 6 p.Article

Viral host-range factor C7 or K1 is essential for modified vaccinia virus Ankara late gene expression in human and murine cells, irrespective of their capacity to inhibit protein kinase R-mediated phosphorylation of eukaryotic translation initiation factor 2αBACKES, Simone; SPERLING, Karin M; ZWILLING, Joachim et al.Journal of general virology. 2010, Vol 91, pp 470-482, issn 0022-1317, 13 p., 2Article

Vaccinia Virus-Mediated Inhibition of Type I Interferon Responses Is a Multifactorial Process Involving the Soluble Type I Interferon Receptor B18 and Intracellular ComponentsWAIBLER, Zoe; ANZAGHE, Martina; FRENZ, Theresa et al.Journal of virology. 2009, Vol 83, Num 4, pp 1563-1571, issn 0022-538X, 9 p.Article

Vaccination with recombinant modified vaccinia virus ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challengeANTONIS, Adriaan F. G; VAN DER MOST, Robbert G; SUEZER, Yasemin et al.Vaccine. 2007, Vol 25, Num 25, pp 4818-4827, issn 0264-410X, 10 p.Article

A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)MEYER, Ralf G; BRITTEN, Cedrik M; BERNHARD, Helga et al.Cancer immunology and immunotherapy. 2005, Vol 54, Num 5, pp 453-467, issn 0340-7004, 15 p.Article

Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and manLOTZ, Carina; FERREIRA, Edite Antunes; DREXLER, Ingo et al.International journal of cancer. 2004, Vol 108, Num 4, pp 571-579, issn 0020-7136, 9 p.Article

Vaccine protection from CD4⁺ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigensKOOPMAN, Gerrit; MORTIER, Daniella; HOFMAN, Sam et al.Journal of general virology. 2004, Vol 85, pp 2915-2924, issn 0022-1317, 10 p., 10Article

Recombinant MVA vaccines: dispelling the mythsCOTTINGHAM, Matthew G; CARROLL, Miles W.Vaccine. 2013, Vol 31, Num 39, pp 4247-4251, issn 0264-410X, 5 p.Article

Oncolytic myxoma virus: The path to clinicCHAN, Winnie M; RAHMAN, Masmudur M; McFADDEN, Grant et al.Vaccine. 2013, Vol 31, Num 39, pp 4252-4258, issn 0264-410X, 7 p.Article

The Orthopoxvirus 68-Kilodalton Ankyrin-Like Protein Is Essential for DNA Replication and Complete Gene Expression of Modified Vaccinia Virus Ankara in Nonpermissive Human and Murine CellsSPERLING, Karin M; SCHWANTES, Astrid; STAIB, Caroline et al.Journal of virology. 2009, Vol 83, Num 12, pp 6029-6038, issn 0022-538X, 10 p.Article

Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1KREIJTZ, Joost H. C. M; SUEZER, Yasemin; SUTTER, Gerd et al.The Journal of infectious diseases. 2007, Vol 195, Num 11, pp 1598-1606, issn 0022-1899, 9 p.Article

Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus AnkaraNILSSON, Charlotta; MÄKITALO, Barbro; THORSTENSSON, Rigmor et al.Vaccine. 2001, Vol 19, Num 25-26, pp 3526-3536, issn 0264-410XArticle

Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitopeWÖLFEL, Catherine; DREXLER, Ingo; VAN PEL, Aline et al.International journal of cancer. 2000, Vol 88, Num 3, pp 432-438, issn 0020-7136Article

Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trialKREIJTZ, Joost H. C. M; GOEIJENBIER, Marco; FOUCHIER, Ron A. M et al.Lancet. Infectious diseases (print). 2014, Vol 14, Num 12, pp 1196-1207, issn 1473-3099, 12 p.Article